Our results suggest that in cohorts of highly immune suppressed patients, especially those on B-cell depleting treatments such as anti-CD20 antibodies and BTK inhibitors, a baseline assessment of immunity based on prior treatment history and immunological markers such as IgM levels and CD19+ cell levels may help predict the response to COVID-19 vaccinations and support administration of additional vaccine doses. The gene discussed is BTK; the disease is COVID-19.